Mach, thanks for your clear and insightful analysi
Post# of 9123
According to the expert opinion of Dr. Sebastian Faro, there is nothing on the market that is better than the N-Assay.
Based on Mach's analysis of the N-Assay capturing 20% of the market in two years, beachlover12's net earnings number of $120m and extrapolating shares outstanding to be ~135m, how much would a potential buyout candidate be willing to today pay for just the N-Assay IP?
Currently, at $0.10, the market value of Nanologix is ~$13m. A company could offer $120m for the company and make all its money back in two years! That comes out to $0.92 per share. Remember that this is just for 20% of the GBS market. What company wouldn't love to make an investment that is paid off in just 2 years with years of exponentially growing profit ahead from all the other bacteria? Just another way to look at things....
Since there is nothing else better or cheaper, I don't see why the product wouldn't sell itself with perhaps a little nudge from the right type of lawyers. Hence, I must emphasize Mach's point that the company will likely need to look into subcontracting out the production of the N-Assay if it already isn't doing so. Otherwise, I doubt the company will able to keep up with the demand.
How exciting would it be if such an agreement were announced? This would be a great catalyst as it would imply lots of new future revenues. BIG multiples to earnings are given to companies with such avenues of growth (i.e., Tesla with a forward PE of 81.23 due to their expected growth in revenue streams in China). Who knows? This could be what breaks the manipulator's control of NNLX stock.